Autoreactivity profiles of influenza hemagglutinin broadly neutralizing antibodies

Goran Bajic1, Cees E. van der Poel2, Masayuki Kuraoka3, Aaron G. Schmidt4,5, Michael C. Carroll2, Garnett Kelsoe3,6 & Stephen C. Harrison1,7

Epitope-focused approaches for selective clonal induction of broadly neutralizing antibodies (bnAbs) inform most current vaccine strategies for influenza virus and other rapidly evolving pathogens. The two conserved epitopes on the influenza hemagglutinin (HA) - the “stem” and the receptor-binding site (RBS) on the “head” - are the focus of the current “universal” influenza vaccine development efforts. Because stem-directed serum bnAbs are much less abundant than head-directed ones, we hypothesized that the HA stem bnAbs may be autoreactive and thus eliminated through the mechanisms of self-tolerance. We compared autoreactivity profiles of a set of stem and head-directed bnAbs. Most of the stem bnAbs we examined bound autoantigens; several showed staining of HEp-2 cells. A smaller proportion of the head-directed bnAbs were polyreactive. Gene usage did not correlate with autoreactivity. We suggest that complex foreign antigens may often have surface patches resembling some host epitope; our results indicate that HA stem epitopes resemble a host epitope more frequently than does the RBS.

Successful viral vaccines, such as those for polio or yellow fever, confer long-lasting immunity by priming the immune system to recognize and neutralize the virus. Some viruses, such as influenza and HIV, evade host immune responses through rapid mutation of surface glycoproteins, thereby changing antigenicity and circumventing previously elicited humoral immunity. The response to current influenza vaccines is often effective only against closely matched strains. Identification of broadly neutralizing antibodies (bnAbs) that recognize diverse influenza viruses has suggested the possibility of “universal” influenza vaccines. The viral hemagglutinin (HA), which binds the host cellular receptor sialic acid and mediates viral entry, is the principal target of known bnAbs1. Two conserved regions on HA recognized by bnAbs include the receptor binding site (RBS) on the HA “head” and the membrane-proximal “stem” (Fig. 1a).

RBS-directed bnAbs such as CH67, K03.12 and C05 have sialic acid-like contacts2,3 and may be more common than previously thought4,5. Antibodies targeting the HA stem are generally rarer. Many derive from V(D)J recombinations with the heavy-chain variable-domain gene segment VH1~696. Unlike the RBS-directed antibodies that offer protection through viral neutralization, the primary mechanism of protection of stem-targeting antibodies, in mouse challenge studies, is through Fcγ-R-dependent effector processes such as ADCC7–11.

Analogous classes of HIV bnAbs are those whose members recognize the gp120 CD4-binding site and the gp41 membrane proximal external region (MPER), respectively12,13. The majority of MPER-directed antibodies bind autoantigens14–16, and bnAbs recognizing other epitopes tend likewise to be polyreactive. Deletion by immune tolerance mechanisms might therefore account for the low frequency of antibodies of this kind14.

Does breadth of influenza virus neutralization likewise correlate with autoreactivity? The VH1~69 gene segment, which encodes over two thirds of known HA stem-directed antibodies6, is associated with polyreactive responses in autoimmune pathologies such as Sjögren’s syndrome17 and with certain B-cell cancers18. It has been suggested that VH1~69 antibodies are especially appropriate for stem recognition because they provide a
ready-made, hydrophobic contact surface, including an important contact from HCDR2 residue Phe54 seen in various crystal structures. A previous study showed that stem-directed antibodies bound more tightly to dsDNA, LPS and insulin than did head binders. VH1~69 encoded, anti-HA antibodies that did not bind the stem had much lower affinity for these potential autoantigens, suggesting a correlation between properties that give rise to polyreactivity (e.g., hydrophobicity of the CDR surface and positive charge on HCDR3) and adequate access to stem surfaces occluded on virions. Specific epitopes within the stem and head were not determined. Few, if any, of the antibodies in that panel gave nuclear staining of HEp-2 cells, leading the authors to conclude that the extent of polyreactivity exhibited by stem-directed antibodies might not be pathogenic.

These observations led us to pose two sets of questions. First, for stem-directed antibodies, what are the polyreactivity characteristics of those not encoded by VH1~69? Second, like many non-MPER directed HIV bnAbs,
do RBS-directed influenza HA bnAbs also tend to show polyreactivity? The broader question is, with what probability does any foreign antigen have a B-cell epitope (somewhere on that antigen) similar to an epitope on some host protein.

To examine the polyreactivity of HA-directed antibodies, we chose a 12-antibody panel, six specific for the HA stem and six for the head. Of the latter, five bound the RBS and one a non-RBS head epitope. Ten of the antibodies came directly from donor BCR sequences; one of the stem antibodies was generated through in vitro affinity maturation, and one of the head antibodies came from screening a human-antibody phage display library.

We assayed all twelve monoclonal antibodies (mAbs) for polyreactivity by staining cells of a human epithelial line, HEp-2, routinely used to test for antinuclear antibody (ANA) in autoimmune disorders. None of the HA head-directed bnAbs showed HEp-2 staining (Fig. 1b). Of the six stem-directed mAbs, three (FI6v3, CR6261 and 41-5E04) produced significant HEp-2 immunofluorescent staining (Fig. 1b,c). The pattern of FI6 staining was largely cytoplasmic and filamentous, probably from association with intermediate filament components (Fig. 1b), as the antibody did not co-localize with phalloidin stained actin (Fig. S1D). Antibody 41-5E04 stained HEp-2 cells in a pattern very similar to that of FI6 (Fig. 1b). CR6261 staining (Fig. 1b), although well above background (Fig. 1c), was less intense than the staining by FI6, 41-5E04, or the autoreactive 564 antibody22 (Fig. 1c) but comparable to the control HIV MPER-directed antibody, 2F5 (Fig. 1b,c). CR6261 gave homogeneous cytoplasmic staining with a “fine-speckled” pattern typical of antibodies that bind the Jo-1 histidyl-tRNA synthetase (Figs 1b; S1C)23. It also gave noticeable plasma membrane staining (Fig. 2a). The other nine bnAbs did not yield detectable signal (Fig. 1bc).

We carried out three more specific assays on subsets of the twelve mAbs.

(1) Because anti-phospholipid antibodies are present in autoimmune disorders24–26 and HIV MPER-directed bnAbs 2F5 and 4E10 react with cardiolipin14, we tested HA stem-directed mAbs in a lipid-based ELISA (Fig. 2b–h). CR6261 and 41-5E04 (Fig. 2b,c) bound phosphatidylethanolamine (DOPE), phosphatidylserine (DOPS), phosphatidylcholine (DOPC), sphingomyelin (SM) and cardiolipin (CL), to various degrees, although not as strongly as did the control anti-HIV mAb, 2F5 (Fig. S2). Addition of albumin had no significant effect on the antibody binding to lipids.

(2) We screened with a Luminex assay all twelve mAbs with a panel of purified common autoantigens (Table 1; Fig. 3). HA stem-directed CR6261 and F16 mAbs bound ubiquitin-protein ligase E3A (UBE3A) and the hapten conjugate NP-BSA (Fig. 3). None of the mAbs bound the BSA only control. Consistent with its HEp-2 staining pattern, CR6261 also bound Jo-1. Another HA stem-targeting bnAb, MEDI FY1, showed weak binding with ribonucleoprotein (RNP). C05, the only HA head-directed antibody that reacted with an autoantigen in this assay, bound centromere B.

(3) Our third autoreactivity screen used a ProtoArray microchip15,16, a high-content functional protein microarray, which contains over 9,000 human proteins (Fig. 4).

To assess polyreactivity, the binding patterns of human anti-HA bnAbs were compared to an isotype-matched human myeloma protein 151 K in lot-matched arrays. Essentially, the binding is assessed as a pairwise comparison of signal (anti-HA bnAb) to background (151 K) ratios. As 151 K binds one human protein, betaine-homocysteine methyltransferase 2 (BHMT2)16, it is an appropriate negative control for polyreactivity, and serves as a positive control to identify autoreactivity. Previous studies with this assay led us to define the autoreactivity cutoff for HIV bnAbs as a signal/background ratio greater than 50016, shown as dashed lines in Fig. 4. Because one of the protein antigens is an influenza A HA, however, we could also define for these tests a more specific cutoff limit. 41-5E04, CR6261 and CR9114 had a highly skewed binding distribution, with some degree of association with most of proteins on the array (Fig. 4b–d). F16 interacted with interleukin-15 (IL-15) (Fig. 4a; Table 1) and, to a lesser extent, with human erythropoietin (EPO) and progesterone-induced-blocking factor 1 (PIBF1). We also plotted the distance of each ProtoArray data point from the diagonal as a frequency histogram and defined a “polyreactivity index” (PI) as the Gaussian mean of the distances from the reference line. The PIs of CR6261, 41-5E04 and CR9114 were 0.34, 0.48 and 0.39, respectively, indicating a significant displacement of the frequency histogram (Fig. S2). Three HA head-directed bnAbs K03.12, 6649 and CR8033 showed no reactivity in the protein arrays (Figs 4h,k,l and S2), but C05, H2526 (which derives from the VH1→69 gene segment) and CH67 bound most of the proteins on the array (Fig. 4k,l,g; Table 1).

In summary, CR6261 and F16 stem-directed bnAbs scored positively for autoreactivity in the HEp-2 staining, Luminex-based AtheNA, and ProtoArray assays. CR6261 also bound phospholipids. 41-5E04 anti-HA stem mAb was positive in HEp-2, lipid ELISA and ProtoArray assays. FY1, the precursor of an in vitro affinity-matured antibody (MEDI8852), bound RNP when tested against the AtheNA panel. The heavy chains of these four antibodies derive from VH1→69, 3→30, 3→53 and 6→1, respectively. Another VH1→69-derived stem bnAb, CR9114, was polyreactive in the ProtoArray assay. Although none of the six head-directed bnAbs produced HEp-2 nuclear staining, three had polyreactive profiles. C05 had modest autoantigen reactivity in the AtheNA assay, and C05, H2526 and CH67 showed a significant degree of polyreactivity and recognized autoantigens on protein arrays. C05 was isolated by phage display; it is therefore unlikely to have its naturally paired light chain. H2526 has a VH1→69 derived heavy-chain variable domain. CH67 does not have any evident characteristics predisposing it to polyreactivity. Although previous work suggested that absence of HEp-2 nuclear staining among the stem antibodies in that study diminished the likelihood of pathogenic polyreactivity23, nuclear staining by CR6261, 41-5E04 and F16 (the latter two with heavy chains not derived from VH1→69) and interaction of F16 and CR6261 with UBE3A as well as CR6261 binding to Jo-1 and of CR6261 and 41-5E04 binding to phospholipids suggest that at least some stem antibodies have pathogenic signatures.
From the autoreactivity profiles of the bnAbs we tested, there appeared to be a correlation between epitope and autoreactivity. Five of the six stem-directed antibodies, CR6261, CR9114, FI6, 41-5E04, and MEDI FY1, were autoreactive to varying degrees. Of these, only CR6261 and CR9114 are encoded by V<sub>H</sub>1–69; the others derive...
from the VH3~30, VH3~53 and VH6~1 genes, respectively. MEDI8852 showed no detectable autoreactivity, but as this antibody was evolved in vitro from MEDI FY127, the introduced mutations may have diminished its auto-reactivity profile. Of the six HA head-directed bnAbs, three were polyreactive when assayed on protein arrays, although none were positive in the HEp-2 test. A much larger screen would be needed, however, to conclude that head-directed bnAbs are less prone to autoreactivity than are stem-directed ones.

Influenza HA head epitopes have been under a strong selective immune pressure and have thus been evolving rapidly. Unlike the HA head, the stem has remained largely invariant, probably because its occlusion on virions makes it poorly immunogenic. Anti-HA stem specific antibodies are present in human sera – either natural antibodies or derived from memory - although at low level. Upon (re)exposure to influenza HA in a form that does not occlude the stem (e.g. a split vaccine), one might expect these responses to be rapidly amplified. Yet, in homologous vaccination boost regimens, the immune responses upon re-vaccination are disproportionately skewed towards the globular head epitopes – the head responses increase after re-vaccination, while the stem

| mAb name | IGHV gene | HCDR3 length | Influenza reactivity | HA epitope | HEp-2 cell staining | Luminesx AtheNA panel | ProtoArray polyreactivity indices |
|----------|------------|---------------|----------------------|------------|---------------------|-----------------------|-------------------------------|
| CR6261   | 1~69*01    | 16            | group 1 stem         | + cytoplasmic, nuclear | UBE3A, NP-BSA, Jo-1 | 0.34                  |
| FI6      | 3~30*18    | 15            | group 1 and 2 stem   | + + cytoplasmic, nuclear | UBE3A, NP-BSA | -0.09                |
| 41-SE04  | 3~53       | 20            | group 2 stem         | + + cytoplasmic, nuclear | -         | 0.48                  |
| CR9114   | 1~69*06    | 16            | group 1, 2 and B stem | -          | -                   | 0.39                  |
| MEDI8852 | 6~1*01     | 20            | group 1 and 2 stem   | -          | -                   | 0.02                  |
| FY1      | 6~1*01     | 20            | group 1 and 2 stem   | -          | RNP                 | -0.08                 |
| CH67     | 1~2*04     | 21            | group 1 head, RBS    | -          | -                   | 0.56                  |
| CR8033   | 3~9*01     | 22            | B head, RBS          | -          | -                   | -0.12                 |
| 6649     | 4~39*01    | 19            | group 1 head, side   | -          | -                   | -0.02                 |
| K03.12   | 1~2*02     | 28            | group 1 and 2 head, RBS | -        | -                   | -0.43                 |
| C05      | 3~23*04    | 28            | group 1 and 2 head, RBS | -        | centromere B      | 0.52                  |
| H2526    | 1~69*01    | 23            | group 1 head, RBS    | -          | -                   | 0.66                  |

Table 1. Reactivity of anti-influenza HA human bnAbs with autoantigens. HEp-2 staining: − negative, + positive, ++ bright positive. Luminesx AtheNA: − negative, if positive, autoantigen indicated.

Figure 3. Binding of mAbs CR6261, FI6, C05 and FY1 to autoantigens in Luminesx assays. Serial dilutions of mAbs were incubated with the Luminesx beads and mean fluorescence intensities (MFI) were read. Mouse IgG1 anti-chick gamma globulin (CGG) was used as control.
responses remain the same pre- and post-vaccination\textsuperscript{30}. These data are consistent with purging of stem responses through mechanisms of self-tolerance, but a firm conclusion would require a direct test of purging \textit{in vivo}.

Conservation of stem epitopes over decades of influenza virus variation is consistent with the low abundance of stem-directed antibodies and the consequent absence of immune pressure\textsuperscript{29}. Imprinting from virus encountered in childhood, which biases subsequent responses to vaccination or infection with a later strain\textsuperscript{31}, will then further contribute to the immunodominance of the head. The stem of HA in split vaccines, although largely clustered into rosettes, may be more accessible than on virions, perhaps accounting for the transient appearance of stem-directed antibodies in early recipients of the 2009 vaccine. Suppression by tolerance mechanisms could then explain their failure to persist following subsequent exposure to the same vaccine.

\textbf{Figure 4.} Protein microarray binding of influenza HA bnAbs. (a–l) Representative ProtoArray summary for protein arrays blotted with (a) FI6, (b) 41-SE04, (c) CR6261, (d) CR9114, (e) MEDI8852, (f) FY1, (g) CH67, (h) K03.12, (i) H2526, (j) CR8033, (k) C05, (l) 6649 or 151 K control. Axis values are relative fluorescence signal intensity (MFI) in the 151 K array (y axis) or test mAb array (x axis). Each dot represents the average of duplicate array proteins. A diagonal line indicates equal binding by test mAb and 151 K. Internal controls for loading of mAb and secondary detection reagent were equally bound by mAb pairs (boxes). Dashed lines indicate the 500-fold signal/background ratio defined as the cutoff for autoreactivity. Circles identify protein autoligands recognized by autoreactive bnAbs.
Current research on vaccine strategies for rapidly evolving viral pathogens like HIV and influenza emphasizes epitope-focused, selective clonal induction. For example, recent discussion of a "universal influenza vaccine" has concentrated particularly on HA stem epitopes. The data presented here indicate that strategies focused exclusively on the HA stem— or, indeed, on any single epitope—might fail to induce adequate antibody titers owing to negative selection of autoreactive B cell clones. Including multiple conserved epitopes in an epitope-focused vaccine will probably increase the likelihood of a robust response while also decreasing the likelihood that a single mutation will escape an individual's protective immunity.

Materials and Methods

IgG expression and purification. For IgG production, the genes for the heavy- and light-chain (kappa or lambda) variable domains were synthesized by Integrated DNA Technologies and cloned into pVRC protein expression vectors containing mouse and human heavy- and light-chain constant domains. Briefly, the bnAb V(D)J sequences were cloned into vectors containing mouse or human IgG1 framework using conventional endonuclease restriction digestion, as previously reported. The mouse isotype was used for HEP-2 lipodys ELISA and Luminex screening and the human isotype for ProtoArray microchips. All subsequent secondary reagents were species-specific to limit background signal. Constructs were confirmed by sequencing at the DNA Sequencing Core Facility at Dana Farber Cancer Institute. IgGs were produced by transient transfection of suspension HEK293F cells using polyethylenimine (PEI; Polysciences). Supernatants were harvested 7 days later, clarified by centrifugation and IgGs were purified using Protein G Plus Agarose (Thermo Fisher Scientific): the IgG supernatants were incubated overnight with agarose slurry, eluted with 0.1 M glycine, pH 2.5, neutralized with 1 M Tris-HCl, pH 8.0 and dialyzed against PBS buffer.

HEP-2 cell staining. Ready to use HEP-20–10 slides (Euroimmun; product No. FA 1512-20) were stained according to manufacturer’s instructions with minor modifications. Recombinant mAbs (mouse IgG1) were diluted to 5 µg/ml or 25 µg/ml in block buffer (0.1% tween, 0.5% BSA in PBS). After one hour of incubation with the mAbs, slides were washed in block buffer and stained with goat anti-mouse IgG-Alexa488 (Life Technologies) and 2 µg/ml DAPI (Sigma) for one hour. After washing, coverslips were mounted with Fluoro-gel (Electron Microscopy Sciences). Images were acquired using an Olympus Fluoview FV1000 confocal system.

Quantification. Images were analyzed using Cell Profiler. Nuclei were identified by the DAPI signal. Cytoplasmic masks were generated by expanding the nuclei mask by 10 pixels and subtracting the original nucleus mask. Mean fluorescent intensities in the Alexa488 channel were quantified for each cell (defined by nucleus).

Phospholipid ELISA. Microtiter plates were coated with 5 µg of lipid 1,2-dioleoyl-sn-glycero-3-phospho-1-serine (DOPS), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), cardiolipin (CL) or sphingomyelin (SM), blocked with phosphate-buffered saline (PBS) supplemented with 2% bovine serum albumin (BSA). Recombinant mouse IgG1 mAbs were diluted in PBS or the blocking buffer. Binding was detected with a secondary rabbit anti-mouse IgG coupled with horse-radish peroxidase (HRP; Invitrogen), incubated with ABTS (2,2’-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid] -diammonium salt) and absorbance read at 405 nm.

Luminex binding assay. Luminex assays were performed as reported. In brief, 5 × 10^6 microspheres (Luminex Corp.) were covalently linked to 25 µg of recombinant protein and incubated with serially diluted mAb (mouse IgG1). Bound mAbs were detected with 4 µg/ml biotinylated goat anti-mouse IgG (SouthernBiotech) (SouthernBiotech), followed by incubation with 25 µg/ml streptavidin-PE (BD). Fluorescence was measured on a Bio-Plex instrument (Bio-Rad).

ProtoArrays. Recombinant human IgG1 mAbs were screened for binding on protein microarrays (ProtoArray) (catalog no. PAH0525101; Invitrogen) precoated with >1,000 human proteins in duplicate. The binding patterns of human anti–IA bnAbs were compared to the human myeloma protein 151 K in lot-matched arrays. Array-bound anti-human IgG served as the loading control for the detection Ab, and array-bound human IgG served as the loading control for the secondary reagent. Abs were screened for reactive antigens on protein microarrays following the manufacturer’s instructions and as described previously. The ProtoArray microarray (Invitrogen) was blocked and incubated on ice with 2 µg/ml of HA mAb or isotype control 151 K for 90 min. Ab binding to array protein was detected with 1 µg/ml of Alexa Fluor 647-labeled anti-human IgG secondary Ab (Invitrogen). The ProtoArray microarrays were scanned using a GenePix 4000B scanner (Molecular Devices) at 635 nm, with 10-µm resolution. Fluorescence intensities were quantified with GenePix Pro 5.0 program (Molecular Devices) using lot-specific protein location information provided by the microarray manufacturer.

References
1. Skehel, J. J. & Wiley, D. C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. *Annu Rev Biochem* **69**, 531–569 (2000).
2. Ekiert, D. C. et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. *Nature* **489**, 526–532 (2012).
3. Schmidt, A. G. et al. Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody. *Proc Natl Acad Sci USA* **110**, 264–269 (2013).
4. Ekiert, D. C. et al. Viral receptor-binding site antibodies with diverse germline origins. *Cell* **161**, 1026–1034 (2015).
5. McCarthy, K. R. et al. Memory B Cells that Cross-React with Group 1 and Group 2 Influenza A Viruses Are Abundant in Adult Human Repertoires. *Immunity* **48**, 174–184 e179 (2018).
6. Henry Dunand, C. J. & Wilson, P. C. Restricted, canonical, stereotyped and convergent immunoglobulin responses. *Philos Trans R Soc Lond B Biol Sci* **370** (2015).
31. Schmidt, A. G.
34. Neu, K. E., Henry Dunand, C. J. & Wilson, P. C. Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease? Immunity 22, 163–173 (2005).
32. Haynes, B. F., Kelsoe, G., Harrison, S. C. & Kepler, T. B. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 30, 423–432 (2012).
33. Krammer, F. Strategies to induce broadly protective antibody responses to viral glycoproteins. Expert Rev Vaccines 16, 503–513 (2017).
34. Neu, K. E., Henry Dunand, C. J. & Wilson, P. C. Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease? Curr Opin Immunol 42, 48–55 (2016).
35. Krammer, F. & Palese, P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 3, 521–530 (2013).
36. Krammer, F. The Quest for a Universal Flu Vaccine: Headless HA 2.0. Cell Host Microbe 18, 395–397 (2015).
37. Kuraoka, M. et al. Complex Antigens Drive Permissive Clonal Selection in Germinal Centers. Immunity 44, 542–552 (2016).
38. Carpenter, A. E. et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol 7, R100 (2006).
39. Tomaras, G. D. et al. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol 85, 11502–11519 (2011).

Acknowledgements
We thank Guglielmo Venturi and Xiaoyan Nie for Luminesix and ProtoArray screening, Kevin McCarthy and Daniela Fera for the K03.12 and 2F5 antibody DNA constructs respectively, Oliver Sandscheid (EUROIMMUN) for help interpreting the HEp-2 staining patterns, and members of our laboratories for discussions. Sequencing reactions were carried out with an ABI3730xl DNA analyzer at the DNA Resource Core of Dana-Farber/Harvard Cancer Center (funded in part by NCI Cancer Center support grant 2P30CA006516-48). This research was supported by NIH grant P01 AI089618-06. S.C.H. is an Investigator in the Howard Hughes Medical Institute.

Author Contributions
G.B and C.E.v.d.P. designed research. G.B., C.E.v.d.P. and M.K. performed research. G.B., C.E.v.d.P. and M.K. analyzed data. A.G.S. provided crucial reagents and expertise. G.B. wrote the manuscript. M.C.C., G.K. and S.C.H. oversaw the project. All authors edited and commented on the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-40175-8.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019